Apellis Pharmaceuticals, Inc. APLS NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

48/100

1/7 Pass

SharesGrow Intrinsic Value

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Metric	TTM (2025-03 – 2025-12)
Revenue	$1B
Gross Profit	$901.1M
Gross Margin	89.8%
Operating Income	$55.43M
Net Income	$22.39M
Net Margin	2.2%
EPS (Diluted)	$0.17

People Also View

MDGL

Madrigal Pharmaceuticals, Inc.

$524.99

-0.13%

RXDX

Prometheus Biosciences, Inc.

$199.92

+0.09%

BPMC

Blueprint Medicines Corporation

$129.46

+0.14%

CERE

Cerevel Therapeutics Holdings, Inc.

Terns Pharmaceuticals, Inc.

$52.68

+0.13%

AKRO

Akero Therapeutics, Inc.

$54.65

+0.00%

MRTX

Mirati Therapeutics, Inc.

$58.70

-0.17%

Apellis Pharmaceuticals, Inc. APLS NASDAQ

People Also View

Get Undervalued Stock Alerts